-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Evolent Health, Lowers Price Target to $6

Benzinga·08/10/2026 12:09:22
Listen to the news
Canaccord Genuity analyst Richard Close maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $7 to $6.